Description
Topirva 50 mg Tablet is an anticonvulsant medication manufactured by Incepta Pharmaceuticals Ltd., containing Topiramate as the active ingredient. Topiramate is utilized in the management of epilepsy and the prevention of migraines. In epilepsy, it is indicated as monotherapy for adults and children aged 6 years and above with newly diagnosed epilepsy, including generalized tonic-clonic seizures and partial seizures with or without secondary generalization. It is also used as adjunctive therapy for adults and children over 2 years of age who have not achieved adequate control with conventional first-line antiepileptic drugs. In migraine prophylaxis, Topirva is recommended for adults experiencing frequent migraine attacks that significantly interfere with daily activities. The exact mechanisms by which Topiramate exerts its effects are not fully understood but are believed to involve the modulation of voltage-gated sodium channels, GABA-A receptors, and glutamate receptors, leading to a reduction in neuronal excitability. Topirva 50 mg Tablet is typically administered orally, with dosage adjustments based on individual patient needs and response to therapy. Common side effects may include dizziness, fatigue, weight loss, and cognitive disturbances. It is important to use Topirva under the supervision of a healthcare provider, as dosage adjustments may be necessary based on individual response and tolerability
.webp)
.jpg)
.jpg)
.jpeg)
.jpg)
.jpeg)
.jpg)
.jpeg)
.jpg)
 100 IU 3 ML.webp)
 400MG.jpg)
.webp)
.jpg)
.jpg)
.jpeg)
.png)
.webp)
.jpg)
Change Language